Frequent administration of abaloparatide shows greater gains in bone anabolic window and bone mineral density in mice: A comparison with teriparatide.

Makino A, Hasegawa T, Takagi H, Takahashi Y, Hase N, Amizuka N

Bone18 Sept 2020Cited by 20 (Europe PMC)

PMID32950699DOI10.1016/j.bone.2020.115651PepBankPUB-32950699

Publisher page PubMedAsk about this study

Summary

Abaloparatide (ABL) is a novel 34-amino acid peptide analog of parathyroid hormone-related protein. In clinical studies, although ABL showed a greater bone mineral density (BMD) increase than teriparatide (TPTD, human parathyroid hormone 1-34), the responses of ABL to bone formation and resorption markers were weaker, making it difficult to understand the relationship between the bone anabolic window (increase in bone formation versus resorption) and bone mass. In the present study, the effects of ABL and TPTD were compared in mice. Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h). Frequent administration of ABL showed higher BMD with enhancement of trabecular and cortical bone mass and structures than that of TPTD, consistent with the clinical results seen with once daily administration. ABL increased bone formation marker levels more than TPTD with more frequent regimens, while bone resorption marker levels were not different between ABL and TPTD in all regimens. Analysis of bone histomorphometry and gene expression also suggested that ABL increased bone formation more than TPTD, while the effect on bone resorption was almost comparable between ABL and TPTD. The bone anabolic windows calculated from bone turnover markers indicated that ABL enhanced the anabolic windows more than TPTD, leading to a robust increase in BMD. The mechanism by which ABL showed a better balance of bone turnover was suggested to be partly due to the enhanced remodeling-based bone formation involved in Ephb4. Taken together, our findings would help elucidate the mechanism by which ABL shows excellent BMD gain and reduction of fractures in patients with osteoporosis.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study16

16 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice, frequent abaloparatide administration produced higher BMD than teriparatide.
In plain wordsIn mice, frequent abaloparatide treatment increased bone density more than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseBone mineral density
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
Frequent administration of ABL showed higher BMD with enhancement of trabecular and cortical bone mass and structures than that of TPTD, consistent with the clinical results seen with once daily administration.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069901
02AnimalAnimal study (in vivo)Efficacy outcome
In mice, frequent teriparatide administration produced lower BMD than abaloparatide.
In plain wordsIn mice, frequent teriparatide treatment produced lower bone density than abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBone mineral density
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
Frequent administration of ABL showed higher BMD with enhancement of trabecular and cortical bone mass and structures than that of TPTD, consistent with the clinical results seen with once daily administration.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069902
03AnimalAnimal study (in vivo)Efficacy outcome
In mice, frequent abaloparatide administration enhanced trabecular and cortical bone mass and structures more than teriparatide.
In plain wordsIn mice, frequent abaloparatide treatment improved bone mass and structure more than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTrabecular and cortical bone mass and structure
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
Frequent administration of ABL showed higher BMD with enhancement of trabecular and cortical bone mass and structures than that of TPTD, consistent with the clinical results seen with once daily administration.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069903
04AnimalAnimal study (in vivo)Efficacy outcome
In mice, frequent teriparatide administration enhanced trabecular and cortical bone mass and structures less than abaloparatide.
In plain wordsIn mice, frequent teriparatide treatment improved bone mass and structure less than abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTrabecular and cortical bone mass and structure
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
Frequent administration of ABL showed higher BMD with enhancement of trabecular and cortical bone mass and structures than that of TPTD, consistent with the clinical results seen with once daily administration.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069904
05AnimalAnimal study (in vivo)Efficacy outcome
In mice, more frequent abaloparatide regimens increased bone formation markers more than teriparatide.
In plain wordsIn mice, frequent abaloparatide treatment increased bone formation markers more than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseBone formation markers
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
ABL increased bone formation marker levels more than TPTD with more frequent regimens, while bone resorption marker levels were not different between ABL and TPTD in all regimens.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069905
06AnimalAnimal study (in vivo)Efficacy outcome
In mice, more frequent teriparatide regimens increased bone formation markers less than abaloparatide.
In plain wordsIn mice, frequent teriparatide treatment increased bone formation markers less than abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBone formation markers
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
ABL increased bone formation marker levels more than TPTD with more frequent regimens, while bone resorption marker levels were not different between ABL and TPTD in all regimens.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069906
07AnimalAnimal study (in vivo)Efficacy outcome
In mice, bone resorption marker levels did not differ between abaloparatide and teriparatide across regimens.
In plain wordsIn mice, bone breakdown markers did not differ between abaloparatide and teriparatide across regimens.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeBone resorption markers
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
ABL increased bone formation marker levels more than TPTD with more frequent regimens, while bone resorption marker levels were not different between ABL and TPTD in all regimens.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069907
08AnimalAnimal study (in vivo)Efficacy outcome
In mice, bone resorption marker levels did not differ between teriparatide and abaloparatide across regimens.
In plain wordsIn mice, bone breakdown markers did not differ between teriparatide and abaloparatide across regimens.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone resorption markers
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
ABL increased bone formation marker levels more than TPTD with more frequent regimens, while bone resorption marker levels were not different between ABL and TPTD in all regimens.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069908
09AnimalAnimal study (in vivo)Efficacy outcome
In mice, histomorphometry and gene expression suggested greater bone formation with abaloparatide than teriparatide.
In plain wordsIn mice, tissue and gene analyses suggested more bone formation with abaloparatide than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseBone formation by histomorphometry and gene expression
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
Analysis of bone histomorphometry and gene expression also suggested that ABL increased bone formation more than TPTD, while the effect on bone resorption was almost comparable between ABL and TPTD.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069909
10AnimalAnimal study (in vivo)Efficacy outcome
In mice, histomorphometry and gene expression suggested less bone formation with teriparatide than abaloparatide.
In plain wordsIn mice, tissue and gene analyses suggested less bone formation with teriparatide than abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBone formation by histomorphometry and gene expression
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
Analysis of bone histomorphometry and gene expression also suggested that ABL increased bone formation more than TPTD, while the effect on bone resorption was almost comparable between ABL and TPTD.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069910
11AnimalAnimal study (in vivo)Efficacy outcome
In mice, histomorphometry and gene expression suggested comparable bone resorption effects with abaloparatide and teriparatide.
In plain wordsIn mice, tissue and gene analyses suggested similar bone breakdown effects with abaloparatide and teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeBone resorption by histomorphometry and gene expression
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
Analysis of bone histomorphometry and gene expression also suggested that ABL increased bone formation more than TPTD, while the effect on bone resorption was almost comparable between ABL and TPTD.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069911
12AnimalAnimal study (in vivo)Efficacy outcome
In mice, histomorphometry and gene expression suggested comparable bone resorption effects with teriparatide and abaloparatide.
In plain wordsIn mice, tissue and gene analyses suggested similar bone breakdown effects with teriparatide and abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBone resorption by histomorphometry and gene expression
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
Analysis of bone histomorphometry and gene expression also suggested that ABL increased bone formation more than TPTD, while the effect on bone resorption was almost comparable between ABL and TPTD.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069912
13AnimalAnimal study (in vivo)Efficacy outcome
In mice, abaloparatide enhanced the bone anabolic window more than teriparatide.
In plain wordsIn mice, abaloparatide increased the balance of bone formation over breakdown more than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseBone anabolic window
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
The bone anabolic windows calculated from bone turnover markers indicated that ABL enhanced the anabolic windows more than TPTD, leading to a robust increase in BMD.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069913
14AnimalAnimal study (in vivo)Efficacy outcome
In mice, teriparatide enhanced the bone anabolic window less than abaloparatide.
In plain wordsIn mice, teriparatide increased the balance of bone formation over breakdown less than abaloparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBone anabolic window
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
The bone anabolic windows calculated from bone turnover markers indicated that ABL enhanced the anabolic windows more than TPTD, leading to a robust increase in BMD.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069914
15AnimalAnimal study (in vivo)Mechanism
In mice, enhanced remodeling-based bone formation involving Ephb4 may partly explain abaloparatide's better bone turnover balance versus teriparatide.
In plain wordsIn mice, enhanced bone remodeling involving Ephb4 may partly explain abaloparatide's better bone turnover balance compared with teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseEphb4-associated remodeling-based bone formation
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
The mechanism by which ABL showed a better balance of bone turnover was suggested to be partly due to the enhanced remodeling-based bone formation involved in Ephb4.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069915
16AnimalAnimal study (in vivo)Mechanism
In mice, enhanced Ephb4-associated remodeling-based bone formation may partly explain abaloparatide's better bone turnover balance versus teriparatide.
In plain wordsIn mice, enhanced bone formation involving Ephb4 may partly explain abaloparatide's better bone turnover balance compared with teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableEphb4-associated remodeling-based bone formation
Study
mousen: not reported in source
Bone turnover and bone mass
Comparator
Abaloparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
QD: 30 μg/kg every 24 h; BID: 15 μg/kg every 12 h; TID: 10 μg/kg every 8 hAs given in this study (mouse).
Source sentences
Summary
The mechanism by which ABL showed a better balance of bone turnover was suggested to be partly due to the enhanced remodeling-based bone formation involved in Ephb4.
2 context sentences(design, population, supporting numbers)
Summary · context
In the present study, the effects of ABL and TPTD were compared in mice.
Summary · context
Given that the rate of bone turnover is higher in rodents than in humans, the comparison was made with several administration regimens providing equivalent daily dosages: once daily (QD, 30 μg/kg every 24 h), twice daily (BID, 15 μg/kg every 12 h), or three times a day (TID, 10 μg/kg every 8 h).
Show in the study text Report a problemFND-3295069916

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.